Sciatica Pipeline Insight
DelveInsight’s, “Sciatica - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Sciatica pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Sciatica also known as sciatic neuralgia or sciatic neuropathy—is mild to intense low back pain that travels into the left or right leg. This pain can be made worse by certain movements such as twisting, bending, or coughing. Sciatica affects 10 to 40 percent of the population, classically around 40 years of age. Sciatica is caused by compression or irritation of one or more of the five sets of nerve roots in the lower back. Pain from sciatic nerve compression may feel dull, sharp, and/or create a burning sensation. It may also be accompanied by intermittent shocks of shooting pain beginning in the buttock and traveling downward into the back and/or side of the thigh and/or leg (also known as radiating pain).
"Sciatica - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sciatica pipeline landscape is provided which includes the disease overview and Sciatica treatment guidelines. The assessment part of the report embraces, in depth Sciatica commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sciatica collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Sciatica R&D. The therapies under development are focused on novel approaches to treat/improve Sciatica.
Sciatica Emerging Drugs Chapters
This segment of the Sciatica report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Sciatica Emerging Drugs
STX-015: Sollis Therapeutics
STX-015 is an Alpha 2 adrenergic receptor agonist being developed by Sollis Therapeutics for the treatment to sciatica. Currently, it is in Phase III stage of clinical trial evaluation.
SP-102: Scilex Holding
SP-102 is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain (sciatica), and it contains no preservatives, surfactants, solvents, or particulates. If approved by the FDA, the SP-102 formulation will be available in a pre-filled syringe and will be administered by epidural injection. Based on preclinical and clinical studies, it extends the residency time at the site of injection and does not show the safety concerns that led the FDA to warn against using other injectable steroid formulations by the epidural route of administration.
Further product details are provided in the report……..
Sciatica: Therapeutic Assessment
This segment of the report provides insights about the different Sciatica drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Sciatica
There are approx. 5+ key companies which are developing the therapies for Sciatica. The companies which have their Sciatica drug candidates in the most advanced stage, i.e. phase III include, Sollis Therapeutics.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Sciatica pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Sciatica: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sciatica therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sciatica drugs.
Sciatica Report Insights
- Sciatica Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Sciatica Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Sciatica drugs?
- How many Sciatica drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sciatica?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sciatica therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Sciatica and their status?
- What are the key designations that have been granted to the emerging drugs?